Neuraxis, Stock Today
| NRXS Stock | 2.10 0.03 1.41% |
PerformanceVery Weak
| Odds Of DistressLow
|
Neuraxis, is selling for under 2.10 as of the 29th of March 2025; that is 1.41% down since the beginning of the trading day. The stock's lowest day price was 2.07. Neuraxis, has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 27th of February 2025 and ending today, the 29th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of August 2023 | Category Healthcare | Classification Health Care |
Neuraxis, is entity of United States. It is traded as Stock on NYSE MKT exchange. The company has 7.22 M outstanding shares of which 11.2 K shares are now shorted by private and institutional investors with about 0.53 trading days to cover. More on Neuraxis,
Moving against Neuraxis, Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Neuraxis, Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Brian Carrico | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Medical Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Medical Equipment, Health Care, Biotechnology, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Neuraxis, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Neuraxis,'s financial leverage. It provides some insight into what part of Neuraxis,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Neuraxis, (NRXS) is traded on NYSE MKT Exchange in USA. It is located in 11611 North Meridian Street, Carmel, IN, United States, 46032 and employs 8 people. Neuraxis, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.16 M. Neuraxis, conducts business under Biotechnology sector and is part of Health Care industry. The entity has 7.22 M outstanding shares of which 11.2 K shares are now shorted by private and institutional investors with about 0.53 trading days to cover.
Neuraxis, generates negative cash flow from operations
Check Neuraxis, Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Neuraxis, is USD15.16 Million. Neuraxis, holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Neuraxis, Ownership Details
Neuraxis, Historical Income Statement
Neuraxis, Stock Against Markets
Neuraxis, Corporate Directors
| Dan Clarence | COO Director | Profile | |
| Thomas Carrico | Chief Director | Profile | |
| Gary Peterson | Director Founder | Profile | |
| Christopher DDS | Director Founder | Profile |
Additional Tools for Neuraxis, Stock Analysis
When running Neuraxis,'s price analysis, check to measure Neuraxis,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuraxis, is operating at the current time. Most of Neuraxis,'s value examination focuses on studying past and present price action to predict the probability of Neuraxis,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuraxis,'s price. Additionally, you may evaluate how the addition of Neuraxis, to your portfolios can decrease your overall portfolio volatility.